The DESCAR-T registry was created at the request of the French Health Authorities to collect data to consolidate knowledge on the short- and long-term efficacy and safety of all CAR T-cell therapies marketed in France.
The biopharmaceutical company Bristol Myers Squibb (BMS) develops and markets CAR T-cells therapies, indicated for the treatment of several hematological malignancies such as lymphoma and multiple myeloma.
In preparation for the arrival on the market of their own CAR-T, BMS contacted LYSARC to conduct an analysis based on the DESCAR-T registry. The objective was to better understand the profile of patients diagnosed with B-cell lymphoma treated with CAR-T already marketed at the time, as well as to better understand the efficacy and safety of these new therapies in real life (without information on the type of CAR-T received).
LYSARC performed the analysis and provided BMS with only descriptive reports, containing only anonymized results (i.e., it will not be possible to link to patients from the data contained in these reports).
Analyses for this project were performed in 2021 on data from patients treated in France with CAR T-cells for B-cell lymphoma and included in the registry before April 12th, 2021.
For patients included in the registry, if you would like more information about the processing of your data in the DESCAR-T Registry, you can contact the doctor at your care center for your CAR-T treatment or make a request at dpo@lysarc.org. You can find more details about your rights regarding your personal data on the homepage, in the section “Je participe ou j’ai participé à un essai“, or in the Patient Information Leaflet you received at the time of your inclusion in the registry.